Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It depends on if any information is released by the company based on the tweet from today:
With the emergence of variants of concern and concerns with Vaccine effectiveness in the face of viral mutations, Enzolytics comes up with a groundbreaking solution. Big news coming up next week. #SARS-CoV2 #mutations #AI #patents #innovation #monoclonalantibody #enzc
3:03 PM · Feb 21, 2021·Twitter Web App
TWEETS discovered TWEETS uncovered Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced. Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.
ENZC mentioned using AI to help identify conserved , immutable targets against HIV virus and the SARs-Cov-2 virus in their 2020 year end update. In just about a month later on February 1, 2021 ENZC announces in a press release it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. In the same release they and I quote:
Then comes the TWEETS:
So we have a tweet from February 18, 2021 mentioning going one step beyond, AI, abrogate the harmful effects of the variations of mutations and COVID-19.
Then on February 21, 2021 we have a tweet mentioning emergence of variants of concern, concerns with Vaccine effectiveness in the face of viral mutations, groundbreaking solution, big news coming up next week, mutations, AI, patents, innovation and monoclonal antibody.
So the tweets make sense because in the February 1, 2021 PR ENZC said and I quote:
Now what is going to patent points to something to do with SARS-Cov-2 based on the information in the tweet,
Supporting DATA:
Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV and SARS-CoV-2 viruses. In addition to those primary targets on these viruses already known to us, we have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.
The significance of this step is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective, initially developed therapeutics. We have all now heard of the new variants of the CoronaVirus that have just surfaced this week in the United Kingdom and South Africa. Such variants have been found to now exist in the U.S. Due to mutation, these variants have slightly different structures from the virus as initially introduced into the U.S. and will require different therapeutics to address them. The necessary response to such mutations is to identify sites on the virus that do not mutate - that are immutable - and to produce monoclonal antibodies targeting these immutable sites. Using artificial intelligence, we expect to be able to identify these sites such that antibodies may be produced targeting them. This is one of our focuses.
https://marketwirenews.com/news-releases/enzolytics-inc-2020-year-end-update-6713954951124293.html
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies.
The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.
The significance of producing monoclonal antibodies against conserved target sites on targeted viruses is made evident by the mutant strains of the CoronaVirus currently surfacing in the U.S, South Africa, Brazil, United Kingdom and around the world. The same virus mutation exists with HIV, as well as other well-known viruses. As a virus mutates, a therapeutic becomes ineffective when it neutralizes by attacking a site that changes. By targeting an immutable site, a therapeutic is not affected by the mutation. This is well understood by the necessity to produce a new flu vaccine with each flu season, namely because the flu virus mutates. Producing therapeutics that target a conserved site on viruses makes possible the production of a therapeutic that is not rendered ineffective by virus mutation, and therefore can be applied successfully both universally around the world and durably over time.
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
At Enzolytics, we go one step beyond by applying Artificial Intelligence to abrogate the harmful effects of the variations that might be more transmissible; more lethal than merely just "monitoring" and "identifying" the virus mutations.#ENZC#COVID-19
1:28 PM · Feb 18, 2021·Twitter Web App
With the emergence of variants of concern and concerns with Vaccine effectiveness in the face of viral mutations, Enzolytics comes up with a groundbreaking solution. Big news coming up next week. #SARS-CoV2 #mutations #AI #patents #innovation #monoclonalantibody #enzc
3:03 PM · Feb 21, 2021·Twitter Web App
Welcome back Jim,
Been praying for you and Texas. I have a lot of friends there. I lived in Texas 3 different times 78-80, 82-84 (Austin), 96-98 (San Antonio) and never seen a snow flake. Cold freezing days here and there but never a flake. Glad you ok and welcome back.
Texas A&M University
BIOSCIENCE BUSINESS ACCELERATOR
If you represent an emerging life science technology company, this is your opportunity to collaborate with a top-tier research university and establish your presence on campus, in our dedicated Business Accelerator space.
Speed Up the Commercialization Process
By leasing space in the Texas A&M Bioscience Business Accelerator, located in the Texas A&M Institute for Preclinical Studies (TIPS) facility, you will maximize your access to comprehensive research services and product development support—from inception through clinical trials.
Standard Lease Terms
Standard leasing terms are available for one year of occupancy, with the possibility of annual renewal for two additional years at modest rate increases. Annual renewal consideration is subject to tenants achieving mutually-agreeable technical and business development milestones during their previous lease term.
Business and technology services are designed to allow tenants to graduate from the accelerator within three years. Graduates are encouraged to expand operations into available space in the adjacent Texas A&M University Research Park.
Rental rates are variable based on the growth stage of the applicant and level of engagement between the applicant and the A&M System. Preference will be given to new business ventures and to those companies actively engaging the Texas A&M research community.
Included with Lease
• Office furnishings
• Use of conference rooms and auditorium
• Utilities (excluding any special utility needs)
• Secure key access
• Shared reception services
• Janitorial services
• Use of kitchen and dining area
• Mailbox with dedicated street address
Evaluation Criteria
Tenants are selected based on anticipated growth and potential to provide economic benefits to Texas and the Research Valley, as well as create opportunities for members of the A&M System; Texas A&M faculty, researchers, and students; and local businesses.
Applications are evaluated on the following criteria:
• Legal status
• Biotechnology-based product or service
• Growth potential/economic benefits
• Business plan
• Physical requirements
• Financial capacity
https://vpr.tamu.edu/a-m-research/factsheets/pdfs/bioscience-business-accelerator
UPDATE: Dow rises and broader market aims to halt 3-session slide to end holiday-shortened week
Today 9:41 AM ET (MarketWatch)Print
By Mark DeCambre
U.S. equity benchmarks were rising modestly Friday morning as the stock market attempted to halt a three-day losing streak for the S&P 500 and Nasdaq Composite.
Equities have been supported by the prospect of another round of fiscal stimulus from Washington, easy-money policies from the Federal Reserve, and the beginning of a recovery from the COVID-19 pandemic as vaccines are rolled out, but rising U.S. bond yields have raised questions about valuations.
How are stock benchmarks performing?
On Thursday (https://www.marketwatch.com/story/dow-futures-retreat-ahead-of-weekly-jobless-claims-report-11613651815?mod=market-snapshot), the Dow snapped a record winning streak, while the Nasdaq Composite and S&P 500 booked their third straight declines, representing the longest losing streak for the Nasdaq since October and the longest string of losses for the Dow since the four-session skid ended Dec. 14.
For the week, the Dow is aiming for a weekly gain of about 0.1%, the S&P 500 is on track for a 0.5% weekly decline, while the Nasdaq is on pace for a 1.6% weekly skid, based on Thursday's close.
What's driving the market?
Weakness in the labor market and worries about rising bond yields have put pressure on the broader equities market this week, especially after a surprise increase in the number of Americans seeking jobless benefits in the latest data weighed on the outlook.
On Friday, the market will be on the lookout for data on the U.S. services and manufacturing sectors that are due midmorning, as well as a report on existing home sales.
Market participants have been expecting further government spending to help mitigate the economic damage from the COVID pandemic, with ongoing negotiations in Congress on the Biden administration's $1.9 trillion aid package.
During a CNBC interview on Thursday evening, U.S. Treasury Secretary Janet Yellen advocated (https://www.marketwatch.com/story/yellen-warns-against-scaling-back-bidens-1-9-trillion-coronavirus-relief-package-01613694101)for more rather than less aid for Americans and said that the risks of doing too little outweighed those for doing too much.
"We think it's very important to have a big package that addresses the pain this has caused--15 million Americans behind on their rent, 24 million adults and 12 million children who don't have enough to eat, small businesses failing," Yellen told CNBC (https://www.marketwatch.com/story/yellen-warns-against-scaling-back-bidens-1-9-trillion-coronavirus-relief-package-01613694101). The House of Representatives will try to pass a $1.9 trillion coronavirus relief plan before the end of February, Speaker Nancy Pelosi said Thursday.
There are also growing expectations that the coronavirus vaccine rollout will bolster economic recovery in the second half of 2021. The U.S. averaged 72,831 new cases a day in the past week, down 44% from the average two weeks ago, (https://www.marketwatch.com/story/coronavirus-tally-global-cases-of-covid-19-top-11103-million-and-us-death-toll-tops-493000-2021-02-19)while so far 59.1 million vaccine doses have been given, to about 17.8% of the population.
However, optimism around a robust economic rebound has underpinned a rise in U.S. Treasury yields as investors rotate out of government debt and increase their position in assets that might perform well in a so-called reflationary environment.
"Market moves of late-and particularly in the last week-sent a clear story of optimism about the US economy," wrote BofA Global Research analysts, led by U.S. economist, Michelle Meyer, in a research note dated Friday.
"We currently forecast 6.0% GDP growth this year and 4.5% next year, leaving us on the very high end of the economic consensus. The risk is that growth will be even stronger given prospects for greater stimulus," the research team wrote.
UPDATE: Dow falls 250 points as rise in jobless claims and bond yields pressures stocks
Today 1:00 PM ET (MarketWatch)Print
By Mark DeCambre
U.S. stock indexes traded sharply lower Thursday as investors digested economic data showing little improvement in the labor market and weighed a rise in bond yields on worries about potential inflation with oil prices at a 12 month high and copper prices near a decade high.
An increasing pace of coronavirus vaccinations, declining COVID case numbers, good quarterly corporate earnings, and hope for a better economy in the second half of 2021 have helped to lift stocks to record highs this month but investors were finding few reasons to drive stocks higher still.
On Wednesday (https://www.marketwatch.com/story/dow-futures-trade-flat-as-investors-await-retail-sales-fed-minutes-11613565689?mod=market-snapshot), the Dow booked its third straight record close but the S&P 500 and the Nasdaq Composite indexes finished in negative territory.
Market participants were digesting some signs of weakness in the overall U.S. economic recovery, after weekly jobless claims (https://www.marketwatch.com/story/requests-for-unemployment-benefits-climb-to-861-000-and-show-layoffs-still-severe-11613656279?mod=mw_latestnews)came in at 861,000, marking the highest level in a month and reading of manufacturing activity also fell short of expectations.
"The jobless claims data continue to paint a bleak labor market picture with 1.38 million new claims for jobless benefits last week, the highest tally since early December," wrote Lydia Boussour, lead U.S. economist and Gregory Daco, chief U.S. economist at Oxford Economics, in a Thursday note.
"The latest jobless claims data are consistent with the downbeat message from labor market indicators at the start of the year," the economists wrote.
Meanwhile, a reading of manufacturing activity in the Federal Reserve's Philadelphia region, the Philly Fed Manufacturing Index (https://www.marketwatch.com/story/philly-fed-manufacturing-index-slips-to-23-1-in-february-after-large-jump-in-prior-month-11613655964?mod=mw_latestnews), fell to 23.1 in February from 26.5 in prior month. Any reading above zero indicates expansion in the manufacturing sector.
Disappointing economic data was compounded by weaker than expected results from Walmart (WMT) early Thursday, Colin Cieszynski, chief market strategist, at SIA Wealth Management said .
"Walmart, the world's largest retailer, posted disappointing results, suggesting that the strong January for US retail sales reported yesterday may not have been enough to offset November-December weakness," he said in a daily research note.
The U.S. economy has been showing signs of steady, if not rapid, improvement, underscored by retail sales figures, which showed a seasonally adjusted rise of 5.3% in January from a month earlier, while data on manufacturing output has been nearing its best levels in a year.
The data come against the backdrop of declining cases of coronavirus in the U.S., with the nation averaging 77,661 new cases a day in the past week, down 43% from the average two weeks ago, and so far 57.4 million Americans have been vaccinated or 17% of the population, at a rate of 1.61 million doses a day, according to data aggregated by Johns Hopkins University (https://coronavirus.jhu.edu/map.html).
Market participants have pointed to progress on more fiscal stimulus from Congress as one cause for optimism for stock buying on Wall Street. Washington lawmakers are still negotiating the terms of the president's $1.9 trillion COVID aid package. The Biden administration is also next month is expected to release a plan to outline his "Build Back Better" agenda that will focus heavily on infrastructure. On Wednesday (https://www.marketwatch.com/story/biden-labor-leaders-to-talk-coronavirus-aid-infrastructure-at-white-house-meeting-11613585045?mod=robert-schroeder), President Joe Biden laid out some elements of his plans to labor leaders.
However, bets that the economy will eventually improve sometime this year have resurrected fears of a rapid rise in inflation, pushing government bond yields higher, with the 10-year Treasury note around 1.3%, around its loftiest level in over a year. But the prospect of higher borrowing costs are overshadowing risky assets (https://www.marketwatch.com/story/heres-when-the-bond-market-selloff-turns-into-a-problem-for-the-stock-market-11613581702)as they trade at near record highs.
Meanwhile, investors were keeping one eye trained on brutal winter conditions that is causing millions of Americans to remain without power in places like Texas, as winter storms buffet much of the U.S. The weather has delivered a jolt to natural-gas prices and pushed crude-oil values to their highest levels in more than a year (https://www.marketwatch.com/story/u-s-oil-extends-rise-above-61-a-barrel-as-texas-deep-freeze-continues-11613655265?mod=markets).
Separately, the House Financial Services Committee at noon Thursday began questioning several of the principal actors in the GameStop stock saga following public outcry against online trading platform Robinhood and other brokers' decisions to briefly restrict trading in stocks including GameStop Corp. (GME), and AMC Entertainment Holdings(AMC).
In other economic reports, a report on housing showed that building permits rose 10.4% in January to 1.88 million annual rate, while housing starts fell 6% last month (https://www.marketwatch.com/story/a-modest-pause-new-home-construction-falls-as-builders-struggle-with-cold-temperatures-rising-covid-cases-11613656387)to 1.58 million annual rate. And a reading of trade showed that U.S. import prices jumped 1.4% in January, marking the biggest increase since 2012.
All markets are down and have been falling for a few days.
It has been brutal on the OTC.
I have 11 tickers that are in profit territory however they are down today anywhere between 7.11% and 37.50%.
We have been in a bull market for months and it has turn bearish for the last few trading sessions.
Hopefully it is short lived.
Market Snapshot
S&P 500
3,898.48 32.85 (0.83%)
Dow Jones Industrials
31,387.58 225.44 (0.71%)
NASDAQ Composite
13,792.35 173.14 (1.23%)
UPDATE: Dow skids over 200 points at the open as jobless claims hit highest in a month
Today 9:48 AM ET (MarketWatch)Print
By Mark DeCambre
U.S. stock indexes traded lower Thursday morning as investors reacted to disappointing results from big-box retailer Walmart Inc., and parsed a weaker-than-expected update on the state of the U.S. labor market amid the COVID pandemic.
Successful vaccine rollouts, good quarterly results from corporations, and hope of a better economy in the second half of 2021 has helped to lift stocks but equity investors were finding fewer reasons to drive stocks higher as bond yields also staged a steady ascent, indicating higher borrowing costs for individuals and corporations.
On Wednesday (https://www.marketwatch.com/story/dow-futures-trade-flat-as-investors-await-retail-sales-fed-minutes-11613565689?mod=market-snapshot), the Dow booked its third straight record close but the S&P 500 and the Nasdaq Composite indexes finished in negative territory.
Market participants were digesting some signs of weakness in the overall economic recovery, after weekly jobless claims (https://www.marketwatch.com/story/requests-for-unemployment-benefits-climb-to-861-000-and-show-layoffs-still-severe-11613656279?mod=mw_latestnews)came in at 861,000, marking the highest level in a month and reading of manufacturing activity also fell short of expectations.
Economists surveyed by Econoday had expected 768,000 new jobless benefit claims for the week ended Feb. 13, down from 793,000, amid receding cases of COVID-19 in parts of the country and the rollout of vaccines. State continuing jobless claims drop 64,000 to 4.49 million.
"The jobless claims data continue to paint a bleak labor market picture with 1.38 million new claims for jobless benefits last week, the highest tally since early December," wrote Lydia Boussour, lead U.S. economist and Gregory Daco, chief U.S. economist at Oxford Economics, in a Thursday note.
"The latest jobless claims data are consistent with the downbeat message from labor market indicators at the start of the year," the economists wrote.
Meanwhile, a reading of manufacturing activity in the Federal Reserve's Philadelphia region, the Philly Fed Manufacturing Index (https://www.marketwatch.com/story/philly-fed-manufacturing-index-slips-to-23-1-in-february-after-large-jump-in-prior-month-11613655964?mod=mw_latestnews), fell to 23.1 in February from 26.5 in prior month.
Any reading above zero indicates improving conditions. Economists polled by The Wall Street Journal had expected a 19.2 reading. Any reading above zero indicates expansion in the manufacturing sector.
Colin Cieszynski, chief market strategist, at SIA Wealth Management said that disappointing in the data also was compounded by weaker than expected results from Walmart early Thursday.
"Walmart, the world's largest retailer, posted disappointing results, suggesting that the strong January for US retail sales reported yesterday may not have been enough to offset November-December weakness," he said in a daily research note.
The data come against the backdrop of declining cases of coronavirus in the U.S., with the nation averaging 77,661 new cases a day in the past week, down 43% from the average two weeks ago, and so far 57.4 million Americans have been vaccinated or 17% of the population, at a rate of 1.61 million doses a day, according to data aggregated by Johns Hopkins University (https://coronavirus.jhu.edu/map.html).
Thus far, the U.S. economy has been showing signs of steady, if not rapid, improvement, underscored by retail sales figures, which showed a seasonally adjusted rise of 5.3% in January from a month earlier, while data on manufacturing output has been nearing its best levels in a year.
Market participants have pointed to progress on more fiscal stimulus from Congress as one cause for optimism for stock buying on Wall Street. Washington lawmakers are still negotiating the terms of the president's $1.9 trillion COVID aid package. The Biden administration is also next month is expected to release a plan to outline his "Build Back Better" agenda that will focus heavily on infrastructure. On Wednesday (https://www.marketwatch.com/story/biden-labor-leaders-to-talk-coronavirus-aid-infrastructure-at-white-house-meeting-11613585045?mod=robert-schroeder), President Joe Biden laid out some elements of his plans to labor leaders.
Bets that the economy will eventually improve sometime this year has resurrected fears of a rapid rise in inflation, pushing government bond yields higher, with the 10-year Treasury note hanging around 1.3%, around its loftiest level in over a year.
Meanwhile, investors were keeping one eye trained on brutal winter conditions that is causing millions of Americans to remain without power in places like Texas, as winter storms buffet much of the U.S. The weather has delivered a jolt to natural-gas prices and pushed crude-oil values to their highest levels in more than a year.
Separately, the House Financial Services Committee at noon Thursday is set to grill several of the principal actors in the GameStop saga following public outcry against online trading platform Robinhood and other brokers' decisions to briefly restrict trading in stocks including GameStop Corp. (GME), and AMC Entertaintment Holdings(AMC).
In other economic reports, a report on housing showed that building permits rose 10.4% in January to 1.88 million annual rate, while housing starts fell 6% last month to 1.58 million annual rate. And a reading of trade showed that U.S. import prices jumped 1.4% in January, marking the biggest increase since 2012.
They have 90 days to file annual and 45 days for quarterly.
March 30, 2021 is deadline for annual.
The stock price moved up almost 16% signaling that the market like the news (even on low volume) and as more people get wind of the news it could move up more in the days ahead.
What particular catalyst will send ENZC into a continuous upward movement is hard to predict however as they progress in their mission to bring their products to the marketplace we should see a continued appreciation in the stock price.
Patience is key.
Toxicity and ENZC:
Toxicity or should I say "lack there of" is part of ENZC secret sauce.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
http://enzolytics.com/our-technology/
Inactivated Pepsin Fragment (IPF) Technology
One Company technology, invented by Harry Zhabilov the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:
Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.
Decrease in the viral load.
Demonstrated beneficial effect on opportunistic infections.
Demonstrated very good compatibility with all of the other modern antiretroviral drugs.
Demonstrated very good tolerance in all patients and complete absence of side effects.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 also has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulates the immune system.
http://enzolytics.com/our-science/
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the
first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number
ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into
partnership agreements with newcomers, or with companies in different stages of development in the research pipeline,
combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action.
Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching
over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues,
among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents
impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content
How important is TOXICITY?
What is toxicology?
Toxicology is a field of science that helps us understand the harmful effects that chemicals, substances, or situations, can have on people, animals, and the environment. Some refer to toxicology as the “Science of Safety” because as a field it has evolved from a science focused on studying poisons and adverse effects of chemical exposures, to a science devoted to studying safety.
Toxicology uses the power of science to predict what, and how chemicals may cause harm and then shares that information to protect public health. When talking about toxicology it is important to keep a few things in mind.
Not everyone will respond to substances in exactly the same way. Many factors, including the amount and duration of exposure, an individual’s susceptibility to a substance, and a person’s age, all impact whether a person will develop a disease or not. There are times in a person’s life when he or she may be more susceptible to chemicals. These times may include periods of active cell differentiation and growth in the womb and in early childhood, as well as during adolescence, when the brain is continuing to develop. Just because someone is exposed to a harmful substance, does not always mean they will get sick from it.
The dose of the chemical or substance a person is exposed to is another important factor in toxicology. All substances have the potential to be toxic if given to humans and other living organisms in certain conditions and at certain doses or levels. For example, one or two aspirins may be good for you, but taking a bottle of aspirin may be harmful. The field of toxicology tries to understand and identify at what dose and through what exposure a substance poses a hazard.
Toxicologists also realize that even low-dose exposures that may seem insignificant may have biological meaning or lead to an adverse health effect if the exposure is continuous or happens during a critical window of development.
What is a toxicologist?
A toxicologist is a scientist who has a strong understanding of many scientific disciplines, such as biology and chemistry, and typically works with chemicals and other substances to determine if they are toxic or harmful to humans and other living organisms or the environment.
Just like there are different types of doctors, there are different types of toxicology specialists.
A toxicologist working in the pharmaceutical industry, for example, might work to make sure that potential new drugs are safe for testing in clinical trials for humans.
A toxicologist working at the National Toxicology Program (NTP) might be involved in designing and overseeing studies that create a controlled environment that replicates exposures that humans may encounter. NTP toxicologists work to identify hazards from the chemicals or substances they are studying.
https://www.niehs.nih.gov/health/topics/science/toxicology/index.cfm
How does the science of toxicology improve people’s lives?
Toxicology provides critical information and knowledge that can be used by regulatory agencies, decision makers, and others to put programs and policies in place to limit our exposures to these substances, thereby preventing or reducing the likelihood that a disease or other negative health outcome would occur. For example, the state of California used NTP findings to establish the first in the nation drinking water standard for Hexavalent Chromium. This standard will help reduce people’s exposure to this metallic element. Other benefits of toxicology include:
Government agencies have a sound scientific basis for establishing regulations and policies aimed at protecting and preserving human health and the environment.
Companies, such as pharmaceutical and chemical, are able to develop safer products, drugs, and workplaces.
Consumers have access to information that helps them make decisions about their own health and prevent diseases.
When ENZC wants to run it will run and it is nothing the MMs can do to stop it.
They maintained an orderly market when ENZC ran into the .90s and will do the same when the stock is pushed higher by buying pressure.
The toxicity test is a non-issue as we already know the expected results from the 2020 Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
We are looking for Toxicity results from BTS Research. The were required before ENZC could submit an IND application to the FDA. The results of those tests should come back with low toxicity. It more of a formality for FDA protocols.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
The funny news:
The Significance of the Methodology for Producing Fully Human herapeutics Monoclonal Antibodies
They forgot the T in therapeutics.
The most interesting news:
Enzolytics specializes in creation of human neutralizing monoclonal antibodies, not “humanized” mouse or rat counterparts, as are many of mAb therapeutics in pharmaceutical use today. The Company’s technological methodologies have developed an effective, strong and robust portfolio of biologics that have pharmaceutical application with significant benefits to patients or animals in the global marketplace. From an identified and created parent hybridoma cell line, four distinct and effective products can be produced: (1) fully human neutralizing monoclonal antibody—directed against any pathogen based disease entity—through use in passive immunotherapy; (2) an effective humoral active vaccine that is safe and effective; (3) an oral mini-antibody peptide based medication with an efficacy that is equivalent to the immunologic capacity of the monoclonal antibody produced by parent hybridoma cell; and (4) an entry-fusion inhibitor that is immunologic in character and scope. The applications are broad, effective and beneficial for immunotherapeutic use.
Hybridoma technology is a method for producing large numbers of identical antibodies (also called monoclonal antibodies). This process starts by injecting a mouse (or other mammal) with an antigen that provokes an immune response. A type of white blood cell, the B cell, produces antibodies that bind to the injected antigen. These antibody producing B-cells are then harvested from the mouse and, in turn, fused with immortal B cell cancer cells, a myeloma,[clarification needed] to produce a hybrid cell line called a hybridoma, which has both the antibody-producing ability of the B-cell and the longevity and reproductivity of the myeloma. The hybridomas can be grown in culture, each culture starting with one viable hybridoma cell, producing cultures each of which consists of genetically identical hybridomas which produce one antibody per culture (monoclonal) rather than mixtures of different antibodies (polyclonal). The myeloma cell line that is used in this process is selected for its ability to grow in tissue culture and for an absence of antibody synthesis. In contrast to polyclonal antibodies, which are mixtures of many different antibody molecules, the monoclonal antibodies produced by each hybridoma line are all chemically identical.
The production of monoclonal antibodies was invented by César Milstein and Georges J. F. Köhler in 1975. They shared the Nobel Prize of 1984 for Medicine and Physiology with Niels Kaj Jerne, who made other contributions to immunology. The term hybridoma was coined by Leonard Herzenberg during his sabbatical in César Milstein's laboratory in 1976–1977.[1]
We don't need your summary. You can't make that up.
Too cool. You made a great move.
Thanks for sharing
ENZC has so much going on that it is hard to grasp. They have in their arsenal the future of medical care in the way of therapeutic platforms first for HIV and Coronavirus and then for 14 more viruses. CEO Charles Cotropia stated, "The Company is making significant progress on both of its therapeutic platforms: first, on the identification of prime target sites on both the CoronaVirus and the HIV virus and the creation of neutralizing antibodies directed against these sites, and second, on advancing its ITV-1 peptide therapeutic for patient application in the EU." CSO Harry Zhabilov stated, "With the Bulgarian Drug Administration joining the European Medicine Agency and being recognized under the Mutual Recognition Agreement with the FDA, once we have successfully finished the permitting process the Company will be able to pursue FDA approval for ITV-1. We are currently investigating the required steps but feel confident that this is a viable option for the ITV-1 patented therapy."
The future of health
How innovation will blur traditional health care boundaries
The life sciences and health care industry is on the brink of large-scale disruption. In a future of health that’s defined by radically interoperable data, open yet secure platforms, and consumer-driven care, what role will you play?
In our vision of the future of health, we view radically interoperable data, artificial intelligence (AI), and open, secure platforms as central to the promise of more consumer-focused, prevention-oriented care. AI will enable major scientific breakthroughs, accelerating the creation of new therapies and vaccines to fight diseases. AI-enabled digital therapeutics and personalized recommendations will empower consumers to prevent health issues from developing. AI-generated insights will influence diagnosis and treatment choices, leading to safer and more effective treatments. Additionally, intelligent manufacturing and supply chain solutions will ensure the right treatments and interventions are delivered at the exact moment needed by the patient. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/future-of-health.html?id=us:2ps:3gl:fohc4:awa:lshc:121420:ad3:kwd-472491030708:the%20%2Bfuture%20of%20%2Bmedicine&gclid=CjwKCAiAsaOBBhA4EiwAo0_AnCsF0fPTERNdE4xTI2mbc961uiNTuuR1QoDHglNSC8VOJwNsgqwMIBoC5SoQAvD_BwE
Monoclonal Antibody Techniques
Monoclonal antibodies (mAbs) are monovalent antibodies which bind to the same epitope and are produced from a single B-lymphocyte clone. Monoclonal antibodies are important tools used in biomedical research, in diagnosis of diseases, and in treatment of such diseases as infections and cancer.
What is the value of monoclonal antibody technology?
Monoclonal antibody technology allows us to produce identical antibody molecules in large scale or industrial yields. It should be noted that the emergence of monoclonal antibody technology makes it possible for a variety of applicationsof monoclonal antibodies.
Single B cell antibody technologies
This approach to produce monoclonal antibodies from single human B cells is based on the analysis of the immunoglobulin gene repertoire and reactivity at the single-cell level by the application of reverse transcription-polymerase chain reaction (RT-PCR) and expression vector cloning.
By recognition of selected cell surface markers, individual mouse or human B cells are isolated (e.g., by fluorescence-activated cell sorting), and genes coding for VL and VH fragments are separately amplified by RT-PCR and combined by PCR. For the final production of human mAbs in vitro, H and L chain gene transcripts from each cell are amplified by RT-PCR before cloning and expression in a mammalian system. This method has the virtue of being able to produce many specific human mAbs in a short period. View more about "Single B cell antibody technologies".
https://www.sinobiological.com/resource/antibody-technical/monoclonal-antibody-technology
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Shares-Current-BioClonetics-Immunotherapeutics-Inc-Update?id=280113
The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.
In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. [color=green][/color]From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".[/color]
Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC:ENZC, Company", )) has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. https://marketwirenews.com/news-releases/enzolytics-inc-engages-bts-research-to-conduct-toxic-6758170663840334.html
The toxicity test is a non-issue as we already know the expected results from the 2020 Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Also I don’t expect a press release on the website because once it is up and running there is no reason to tell us as we will already know.
https://twitter.com/SportsCardsTVMe/status/1361002549608931328
https://twitter.com/drgauravchandra/status/1361006189249757187?s=19
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company's proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics.
Production of the Company's primary anti-HIV monoclonal antibodies is underway at Genscript Labs. Testing of these newly produced monoclonal antibodies is scheduled for early 2021 at the University of Strasbourg in Strasbourg France. Thereafter, Macaque trials are planned at the California National Primate Research Center, Univ. of California, Davis, CA.
Additional information on the progress and Company facilities will be part of the new Company website expected to be rolled out in the coming days.
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
ENZC have accomplished many milestones to get their products to the marketplace. We come a long way in a short period of time however much more work is necessary and unforeseen circumstances to overcome such as the situation in Bulgaria. Getting our first product to the marketplace is a priority as it is needed and will be done as soon as possible. Whether that is weeks or months away is not only up to the company but also any requirements set forth by regulatory agencies as we have seen with the toxicity test. ENZC is fortunate to be at the The Texas A&M Institute for Preclinical Studies (TIPS)
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry and engineering. This direct association with the College of Veterinary Medicine and Biomedical Sciences gives researchers the ability to pursue knowledge in a top research university, where cutting-edge technology and scientists at the head of their field can be accessed.
Nobody in their right mind is going to sell and there is not going to be a massive sell off because the website is down.
The reddit post was well put together.
Worth reading.
https://www.reddit.com/r/smallstreetbets/comments/lgyhto/the_smallest_future_big_pharmaceutical_company/
On May 2, 2018, Dr. Harry moved forward with the FINRA to convert the existing OTC symbol $ECPO to $ENZC, officially creating Enzolytics, Inc. and its New Trading Symbol: ENZC.
With the imperative nature of ending the HIV epidemic, for the following two years, Dr. Harry worked on the back end to forge a relationship with Dr. Joseph Cotropia and his lawyer brother, Charles Cotropia, knowing that their two proprietary technologies combined would be the death knell to the HIV epidemic. Finally, on 10/22/2020, Enzolytics, Inc. announced the appointment of Dr. Charles Cotropia as CEO of ENZC and Dr. Harry Zhabilov as Its CSO, completing the merger of BioClonetics and Enzolytics. As a result, ENZC can now successfully put an end to HIV as well as a host of other deadly diseases.
OPINION
Listen guys, Enzolytics is on the forefront of modern biotechnology, actively discovering new and relevant ways to combat the scourges of mankind, from AI-driven identification of individual viral isolates (strains), exploring ways to implement immunotherapy, to forging new relationships within the pharmaceutical industry in order to get their products into the hands of doctors and ultimately patients. With diamond hands built into our DNA, the sparkling collaboration between members of the leadership team, clean access to forward technologies and labs at Texas A&M, Enzolytics is going to lead the way in building a better, more healthy future for all mankind… and they are going to be creating a lot of value for the shareholders in the process.
The stock price will move according to the the results of the company. Besides the company unlimited potential, the minor results (getting current, new patent, hired PCAOB auditor, toxicity study etc..) management and board of directors has put ENZC on a trajectory of preeminence.
Will ENZC fill the shoes of such an important distinction?
Time will tell.
The company is just in the development stage with some powerful tools in their closet. The have some processes that the MUST go through to get to the final goals of getting products to the marketplace.
ENZC is very fortunate to be at Texas A&M Institute for Preclinical Studies(TIPS)
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry, and engineering.
ENZC have shared their plans, goals mission and commitments as well as updates along the way. What they have shared thus far is just a sliver of what is coming down the road.
We are not even 6 months into this journey and the attention the company is getting is unprecedented. They posses some unique technology that may be the answer to help shutting Covid-19 down or at least keeping it in check.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
When ENZC start to get further along in the process and start to share some updates on the activities below things are going to get real busy up in here and elsewhere.
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study 1st Quarter 2021
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
Anytime
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy. Early 2021
14. Status of ENZC updated website. In the coming days
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be.
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
No thanks needed.
You know what your doing.
I appreciate you and because of people like you that know what they are doing, you bring liquidity to stocks that is necessary for stocks to move.
Leave the traders, flippers, shorters or whomever else wants to come buy and sell this stock alone. Any stock needs liquidity and no stock is going anywhere unless someone is buying and selling. Everybody is not going to be a long and hold for dollars and higher. The more other than longs we have the merrier.
Don't pay them no mind.
Do what you want.
It is your money and your choice.
Don't follow the crowd, follow what is good for you.
FDA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
Our agency has had experience with evolving infectious diseases. Influenza vaccines and diagnostics are often modified each year to address the predicted predominant strains circulating globally. The agency has created and used regulatory processes that facilitate these updates. We will utilize our experience with influenza to help inform a path forward if SARS-CoV-2 variants emerge against which currently authorized vaccines are not sufficiently effective. Similarly, the FDA also has vast experience with HIV developing resistance to antiviral drugs and will follow regulatory pathways to quickly enable new antiviral drug development for resistant virus.
We have already been communicating with individual medical product sponsors to provide information as they evaluate the impact of COVID-19 variants on their products. And as part of our commitment to a public and transparent process, the FDA is developing guidances for diagnostic, therapeutic and vaccine developers to help guide ongoing medical product development.
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
For authorized vaccines, our teams are currently deliberating and discussing the types of data needed to support changes in the composition of the vaccine, either through altering the existing vaccine or through the addition of new vaccine component(s), including how sponsors could demonstrate immune response to new variants through streamlined clinical programs that still gather the crucial data the FDA needs to demonstrate effectiveness, but can be executed quickly to gather this data. To be clear, while we continue to develop an understanding of and address any impact of variants on FDA-regulated products, at this time, available information suggests that the authorized vaccines remain effective in protecting the American public against currently circulating strains of COVID-19.
FDA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
Worth repeating:
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
Our agency has had experience with evolving infectious diseases. Influenza vaccines and diagnostics are often modified each year to address the predicted predominant strains circulating globally. The agency has created and used regulatory processes that facilitate these updates. We will utilize our experience with influenza to help inform a path forward if SARS-CoV-2 variants emerge against which currently authorized vaccines are not sufficiently effective. Similarly, the FDA also has vast experience with HIV developing resistance to antiviral drugs and will follow regulatory pathways to quickly enable new antiviral drug development for resistant virus.
We have already been communicating with individual medical product sponsors to provide information as they evaluate the impact of COVID-19 variants on their products. And as part of our commitment to a public and transparent process, the FDA is developing guidances for diagnostic, therapeutic and vaccine developers to help guide ongoing medical product development.
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
For authorized vaccines, our teams are currently deliberating and discussing the types of data needed to support changes in the composition of the vaccine, either through altering the existing vaccine or through the addition of new vaccine component(s), including how sponsors could demonstrate immune response to new variants through streamlined clinical programs that still gather the crucial data the FDA needs to demonstrate effectiveness, but can be executed quickly to gather this data. To be clear, while we continue to develop an understanding of and address any impact of variants on FDA-regulated products, at this time, available information suggests that the authorized vaccines remain effective in protecting the American public against currently circulating strains of COVID-19.
Scroll to the bottom of the page and click on terms of service.
However if you wait 3700 hours you would be 154 days older and none the smarter as the stock price may be higher.
It is interesting how ENZC has transformed/merged to where it is today. I don't think it was by accident and it was well planned and thought out.
Check this out:
DALLAS, TX / ACCESSWIRE / February 6, 2020 / Enzolytics- (OTC Pink Sheet-ENZC) was notified by FINRA that an unauthorized press release titled, "Enzolytics Inc., Launches Coronavirus Prevention Kit" was distributed to the public. Enzolytics and its management had no knowledge of this press release in any manner, and disavows any information contained in this press release. The company does not have a "Coronavirus Prevention Kit" and finds the claim reckless and fraudulent.
A press release typically begins with the name of the city where it originates from and the current date. It should include an attention-grabbing headline. Always write in the third person, sharing riveting information from an outsider's perspective (as the media would).
The point here is where the press release originated from.
Who is in Dallas?
They must of already been hard at work planning for the merger that wasn't publicly released until September.
I believe there may have been a gentleman's agreement when the next press release came out.
PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public company perspective and allow the achievement of the company objectives.
The immediate goals include:
- Regain Current Status with OTC Markets
- Open operation in the Dallas, Tx area where the company has relocated
- Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe.
- Assist Immunotech Laboratories BG-Europe in the registration of ImmunH as an Immunomodulator for HIV treatment.
- Further our development in North America of our Flagship HIV immune treatment compound IPF
As it relates to the CMO and production of the initial validation batch of our lead product ITV-1, which will be marketed in Europe as ImmunH through our partner, Immunotech Laboratories BG-Europe. This is for the treatment of HIV/Aids, and the validation batch production is for the purpose of Phase IV, as required by the regulatory agencies as part of the mass use permitting process. Upon a successful validation batch, the intention is for full commercialization in Eastern Europe initially, then expansion to additional markets. Enzolytics owns 49% of Immunotech Laboratories BG-Europe.
Do any of those goals sound familiar?
That is all I got however I have one question for the board.
Does anyone What brought these two companies together?
This is an Analysis of what may become of ENZC.
As most of you know I normally regurgitate the information released by ENZC management and post what is to be expected in the coming days, weeks and months.
Today you are getting a one and only special of my expectations, current intelligence gathering and just good old common sense with a sprinkle of humor.
Background:
I spent over 20 years in the Air Force with 15 of those years in Electronic Intelligence. We were task with collecting, analyzing and reporting our findings. It normally was cut and dry as just the facts. What it is, whose it is and where it is. Every once and awhile we may not know what it is and so we have to give an estimation or best guess of what we think it could possibly be. There used to be disagreements amongst the different intelligence agencies that didn’t get resolved until further information was collected or they just agreed to disagree.
Analysis:
ENZC is a penny stock and as with penny stock there is a high risk that one could lose most if not all of their investment. The possibility exist that all we have witness up-to date is one of the most intricate frauds in the history of the stock market.
Now that I that I threw some rocks at you here is some candy.
ENZC is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
Enzolytics' flagship compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
BioClonetics Immunotherapeutics, Inc., a wholly owned subsidiary of Enzolytics, is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the SARS-CoV-2 Coronavirus.
ENZC is in a great position to disrupt the drug market for HIV, Coronavirus, Multiple Sclerosis and other diseases. They have been making great strides to accomplish this and much more progress is necessary to enable them to get their technology to the marketplace. They have been very forthcoming and keep shareholders abreast of certain developments as they move through the necessary processes to reach their intended results.
The beauty of ENZC is the 2 prong punch of the ITV-1 1 (Immune Therapeutic Vaccine-1), and Cl3hmAb (human monoclonal antibody) and the man in Charge, Chares S. Cotropia.
Mr. Cotropia appears to have a well-defined game plan that he has shared with shareholders through press releases and is evident as seen in the share price. The game plan seems to be working beautifully as he pointed out in the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
Now with the way the stock price is performing, objective one from the above paragraph is more likely to happen than not and objective two is already happening.
Why is the stock price exploding?
ACCUMALATION other than retail is my theory.
Someone is accumulating shares and until they get the amount they want the share price will continue on a steady rise. Base on the outstanding share the amount this entity is after is probably in the hundreds of millions of shares. The market makers (MMs) are doing a wonderful job keeping a handle on the situation.
There was stock back in September 2009 called Vermilion( VRML) now called Aspira Women's Health Inc (AWH). It was a bio stock for something to do with ovarian cancer. Anyways haha the FDA approval came through and you all know what happened. Yes the stock rose and rose and rose. Here is what most don’t know unless you followed the story at the time. There were only a handful of shares. I believe less than 7 Million shares yes Seven MILLION shares and it was in bankruptcy.
Estimated Market Cap
$306,344 as of Sep 10, 2009
Outstanding Shares
6,382,166 as of Oct 31, 2008
Authorized Shares
150,000,000 as of Jun 30, 2008
Number of Share Holders of Record
142 as of Mar 31, 2008
Here is a message from this EPIC rise (MUST READ):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=43527270
Here are some data points from VRML:
Date Open High Low Close Volume Adj Close*
Mar 3, 2010 30.00 31.56 29.05 31.50 141,600 31.50
Mar 2, 2010 31.25 31.43 29.50 30.20 113,000 30.20
Mar 1, 2010 32.00 32.70 30.55 31.43 157,700 31.43
Feb 26, 2010 31.00 32.24 31.00 32.03 133,900 32.03
Feb 25, 2010 30.20 31.25 29.05 31.00 124,300 31.00
Feb 24, 2010 28.70 30.25 28.60 30.00 194,000 30.00
Nov 13, 2009 22.70 23.53 22.30 23.20 328,900 23.20
Nov 12, 2009 19.25 23.70 18.80 22.20 896,300 22.20
Nov 11, 2009 18.00 18.95 17.75 18.75 36,000 18.75
Nov 10, 2009 18.60 19.00 17.75 18.25 48,200 18.25
Nov 9, 2009 17.40 19.20 17.40 18.75 119,100 18.75
Oct 14, 2009 15.10 16.00 15.10 15.80 297,400 15.80
Oct 13, 2009 14.65 15.79 13.26 15.25 150,500 15.25
Oct 12, 2009 10.26 14.75 10.25 14.65 396,900 14.65
Oct 9, 2009 11.25 12.00 9.56 10.26 604,600 10.26
Oct 8, 2009 14.80 15.25 12.50 12.50 219,200 12.50
Sep 14, 2009 2.00 4.79 1.99 3.08 2,819,800 3.08
Sep 11, 2009 0.05 1.29 0.05 1.29 1,942,500 1.29
Sep 10, 2009 0.05 0.05 0.05 0.05 1,700 0.05
Sep 9, 2009 0.05 0.05 0.04 0.05 1,700 0.05
Sep 8, 2009 0.04 0.04 0.04 0.04 18,500 0.04
Basically the FDA news sent the stock flying starting September 11, 2009 and it rose steadily until March 2010. It did hit the $20 range and October before retreating back to the teens and from there it did a steady rise to the $30 range by March 2010. With pull backs and consolidations along the way. The interesting part is the MMs did a wonderful job keeping a handle on this epic rise.
I believe ENZC Future EPIC rise will GREATLY over shadow VRML’s rise.
We have an assortment of expertise on this board and it is time for people to use them and listen to them. Case in point Art is a former Wall Street person. He knows the ins and outs of the marketplace and has shared some insights about MMs and people keep harping on the MMs and their games and in reality they are just doing their jobs.
Having Free Nebula moving about the board is a *****(5star) treatment). Don’t now him personally however over the years as I crossed paths with him, he has been pretty good with his information.
Leave the traders, flippers, shorters or whomever else wants to come buy and sell this stock alone. Any stock needs liquidity and no stock is going anywhere unless someone is buying and selling. Everybody is not going to be a long and hold for dollars and higher. The more other than longs we have the merrier.
I hope everyone have great results with their positions in ENZC and many fortunes are created.
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.
Enzolytics' flagship compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
BioClonetics Immunotherapeutics, Inc., a wholly owned subsidiary of Enzolytics, is a Dallas and College Station, Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the SARS-CoV-2 Coronavirus.
ENZC is in a great position to disrupt the drug market for HIV, Coronavirus, Multiple Sclerosis and other diseases. They have been making great strides to accomplish this and much more progress is necessary to enable them to get their technology to the marketplace. They have been very forthcoming and keep shareholders abreast of certain developments as they move through the necessary processes to reach their intended results.
The press release from today has definitive information that ties into previous released press releases showing the ENZC progression towards its intended goals.
1. Production of the Company's primary anti-HIV monoclonal antibodies is underway at Genscript Labs. Testing of these newly produced monoclonal antibodies is scheduled for early 2021 at the University of Strasbourg in Strasbourg France. Thereafter, Macaque trials are planned at the California National Primate Research Center, Univ. of California, Davis, CA.
2. Additional information on the progress and Company facilities will be part of the new Company website expected to be rolled out in the coming days.
3. In addition, the Company offers this update on its progress toward FDA approval of ENZC's licensed ITV-1 Immunotherapy treatment previously tested in human trials in Bulgaria. On April 29, 2019, Bulgaria, as a member of the European Medicines Agency (EMA), was recognized under the Mutual Recognition Agreement (MRA) between the FDA and European Union for medicinal products for human use subject to limitations. This allows drug inspectors to rely upon information from drug inspections conducted within countries recognized under the Treaty.
4. As stated in the year end update, proposals were recently requested from several PCAOB accounting firms to provide quotes for Audits of the Company's current and prior year Financial Statements in order to become fully reporting. The Company has engaged MaloneBailey, LLC of Houston, Texas as its PCAOB accounting firm and has begun the audit process. It is still the Company's plan to complete the two-year audit as quickly as possible but will file the December 31, 2021 Annual Report Financial Statements pursuant to the OTC Markets Pink Basic Disclosure Guidelines immediately upon completion to allow time to complete the two-year audits and remain current with our filings.
We are still waiting for more updates on other activities as ENZC continues on their mission to bring their products to the marketplace.
ENZC news will be released when CHARLES who is Charge has something to report to the shareholders. He has done so in the past and will continue to do so in the future. There is a variety of activities presently going on with ENZC that we know about and many that we don’t.
There have been 15 Press Releases since September 2020 which is about 2 per month. Don’t expect 2 press releases per month but do expect press releases to come when Charles has something to report.
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study 1st Quarter 2021
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
Anytime
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy. Early 2021
14. Status of ENZC updated website. In the coming days
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be.
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
Two licensing agreements were mentioned last month:
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
https://backend.otcmarkets.com/otcapi/company/financial-report/265788/content
Absolutely,
Any mention of ENZC products in other companies patents or papers is value added and may spark interest and inquiries.
As much as all here would love to see a license from Gilead, one must realize Gilead makes billions off of HIV products. Their older drugs were toxic to bone and kidneys and their newer ones aren't much better.
Putting aside remdesivir, the Gilead story right now is one focused on change. The company, which shot to pharmaceutical prominence in 2013 with the Food and Drug Administration approval of the hepatitis-C cure Sovaldi, has lately turned its gaze on oncology. (That’s the thing about developing a cure; at its peak, Sovaldi brought in $10 billion in 2014, but demand fell off as fewer people were in need of treatment.)
Since the beginning of March, the drugmaker has signed two cancer-focused deals: an acquisition of immuno-oncology company Forty Seven Inc. for $4.9 billion, and a three-year research collaboration with Onko-innate in which the biotech received an undisclosed upfront payment. There have also been recent reports that Gilead is considering a stake in Arcus Biosciences Inc., another cancer therapy developer.
The company’s well-known HIV drug portfolio, which made up 74% of total sales last year, got a boost with the 2018 approval of Biktarvy, which brought in $4.7 billion in 2019, up from $1.9 billion in 2018. The drug is on track for $6.8 billion in sales this year, according to a FactSet consensus. And while some analysts have raised questions about how shelter-in-place orders will impact prescription drug sales, “for the most part growth brands are still growing (Biktarvy, Dupixent, Aimovig),” Bernstein analysts wrote on Monday.
ENZC is an answer to Gilead toxicity problems and they can continue to make billions except they would have to share some of those billions with us.
If not Gilead someone will help bring ENZC products to the market.
It appears to be a when not if situation.
Based of the available information I would say there is no agreement that Gilead has licensed an ENZC product.
ENZC has an obligation to report material corporate events.
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc.,entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
https://backend.otcmarkets.com/otcapi/company/financial-report/265788/content
Patent US-7479538
Enzolytics has a License Agreement for US Patent 7479538. The claim is Irreversibly-inactivated Pepsinogen Fragments for Modulating Immune Function.
https://enzolytics.com/patent
Anytime one submits a patent application it is best to cover as many
embodiments as possible.
The mention of ITV-4 and cl3mAb is an embodiment:
[0302] In some embodiments the entry inhibitor that can be combined with an agent of this disclosure is a gp41 inhibitor selected from the group consisting of: albuvirtide, enfuvirtide, griffithsin (gp41/gp120/gp160 inhibitor), BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, Cl3hmAb, PIE-12 trimer and sifuvirtide.
WHY MULTIPLE EMBODIMENTS ARE SO HELPFUL
IP applicants should consider listing multiple embodiments on their patent applications. The Oxford Dictionary defines an embodiment as “the representation or expression of something in a tangible or visible form.” On a patent application, an embodiment is a detailed description of how an invention can be made or used. It’s not enough to assume that this is obvious or implied – it must be explicitly stated to take advantage of maximum protection.
For example, if there are multiple methods of making an invention or if it is an invention that has (or could have) multiple uses, the patent applicant should list every possible embodiment they can imagine in the specification. Doing so makes it less likely that an infringer will later be able to exploit vagueness in the issued patent.
FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=DDC8B7681B747EB0211FDFD143EB73F7.wapp1nB?docId=WO2020263830&tab=PCTDESCRIPTION
CROSS-REFERENCE TO RELATED APPLICATIONS
BACKGROUND
[0003] Dendritic cells (DCs) are the most potent antigen-presenting cell in the body. DCs function to process antigen material and present it on the cell surface to the T cells. DCs act as messengers between the innate and the adaptive immune systems. Fms related tyrosine kinase 3 ligand (FLT3LG, FLT3L, NCBI Gene ID: 2323) selectively expands DCs from bone marrow precursors, as well as promotes proliferation of terminally differentiated DCs in lymphoid and tumor tissues.
[0004] Soluble recombinant human protein forms of FLT3L have a serum half-life in humans of about 12-28 hours after five consecutive subcutaneous (SC) doses, requiring daily administration to the patient over a 28-day therapeutic cycle. Daily administration is undesirable, for both the patient and clinician, and is dose scheduling that does not align with other approved immune-oncology therapeutic agents, which is usually once every 2 to 3 weeks. Longer acting antiviral therapeutic agents are also considered desirable.
SUMMARY
[0005] Provided are FLT3L-Fc fusion proteins that have an extended serum half-life in a human subject, relative to soluble FLT3L.
DETAILED DESCRIPTION
1. Introduction
[0049] Provided are fms related tyrosine kinase 3 ligand (FLT3L) extracellular domain -immunoglobulin fragment crystallizable region (Fc region) fusion proteins that have a serum half-life allowing for administration intervals that coordinates with other approved immuno-oncology therapeutic agents, e.g., about once every 1, 2, 3 or 4 weeks, or longer intervals. The FLT3L-Fc fusion proteins demonstrate favorable expression yields in in vitro culture, have structural properties that allow for efficient large-scale purification and long-term storage. The FLT3L-Fc fusion proteins described herein have an increased serum half-life in comparison to soluble FLT3L. Whereas soluble FLT3L must be administered on a daily basis, the herein described FLT3L-Fc fusion proteins can be administered about once every 1 to 8 weeks, or longer intervals.
HIV Therapeutic Agents
[0294] In various embodiments, the FLT3L-Fc fusion proteins, homodimers, heterodimers, polynucleotides, vectors, lipoplexes, such as LNPs, and/or pharmaceutical compositions, as described herein, are combined with an HIV therapeutic agent.
[0302] In some embodiments the entry inhibitor that can be combined with an agent of this disclosure is a gp41 inhibitor selected from the group consisting of: albuvirtide, enfuvirtide, griffithsin (gp41/gp120/gp160 inhibitor), BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, Cl3hmAb, PIE-12 trimer and sifuvirtide.
WHY MULTIPLE EMBODIMENTS ARE SO HELPFUL
IP applicants should consider listing multiple embodiments on their patent applications. The Oxford Dictionary defines an embodiment as “the representation or expression of something in a tangible or visible form.” On a patent application, an embodiment is a detailed description of how an invention can be made or used. It’s not enough to assume that this is obvious or implied – it must be explicitly stated to take advantage of maximum protection.
For example, if there are multiple methods of making an invention or if it is an invention that has (or could have) multiple uses, the patent applicant should list every possible embodiment they can imagine in the specification. Doing so makes it less likely that an infringer will later be able to exploit vagueness in the issued patent.
Well put Bud-Wiser,
It is good to have a plan when trading stocks.
I am sure many here have their plans as well.
Thanks for sharing
ENZC news will be released when CHARLES who is Charge has something to report to the shareholders. He has done so in the past and will continue to do so in the future. There is a variety of activities presently going on with ENZC that we know about and many that we don’t.
There have been 14 Press Releases since September 2020 which is about 2 per month. Don’t expect 2 press releases per month but do expect press releases to come when Charles has something to report.
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study 1st Quarter 2021
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
Anytime
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
Early 2021
14. Status of ENZC updated website Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
I don't think much is going to change in the short term.
There are lawsuits going on.
I don't know how you justify closing out someone's 4500 share position in a stock at 11:30am for $119 a share and the stock closes at $193 dollars a share.
Is it legal?
There is big money behind what happened and it changed the portfolios of some heavy hitters.
If rules are changed it affects everyone.
Congress phone system was overwhelmed with calls.
The bottom line is people who shorted GME got hurt so bad that have to come up with a better plan for shorting. The hedge fund that took the worst hit had quite a bit of short positions that it took a hefty amount of their other positions to cover. Other hedge funds had to step in to shore up their company.
Shorting is high risk high reward however if one risk too much as in this case and the reward don't come and the worst case scenario happens and the short stock rises watch out.
It is going to be very interesting as to what happens because of this situation in the coming days and weeks.
It will fine the stock market is too important for it not to be.